Ketone bodies can readily be used as an energy substrate for cardiac ATP production in HF [87,94], suggesting that SGLT2 inhibitors could target the myocardial energy deficit that is caused by the altered cardiac fuel use. The gene discussed is SLC5A2; the disease is hydrops fetalis.